Updated:
Verily Life Sciences LLC
Verily Life Sciences was founded in 2015 as an Alphabet subsidiary under CEO Andy Conrad, a former executive at the Clinton Foundation and Pacific Biosciences.
Verily Life Sciences LLC
Verily Life Sciences was founded in 2015 as an Alphabet subsidiary under CEO Andy Conrad, a former executive at the Clinton Foundation and Pacific Biosciences. The entity was created to commercialize healthcare technology using Alphabet's data infrastructure and machine learning capabilities, distinct from Google's core advertising business. Verily invests across digital health, AI/ML diagnostics, and clinical research tools. Its strategy combines internal product development with venture investments and strategic partnerships. The firm has developed platforms such as the Study Watch for clinical trials and Onduo for diabetes management. Confirmed partnerships include a collaboration with Johnson & Johnson for surgical robotics (Verb Surgical) and a joint venture with GlaxoSmithKline for bioelectronic medicines (Galvani Bioelectronics, per Reuters, 2016). Geographically, Verily primarily operates in the United States and has expanded into Europe and Asia through research collaborations. Verily employs several hundred professionals across its South San Francisco headquarters and additional offices in Boston, New York, and Zurich. While total professionals are not publicly disclosed, the organization has grown through acquisitions and hires from academia and pharma. A notable recent activity: in 2023, Verily announced a restructuring that included layoffs and a refocus on core precision health initiatives (per the Wall Street Journal, 2023). Verily also maintains a philanthropic arm focused on global health data access. A structural differentiator is Verily's hybrid model as both an Alphabet subsidiary and a quasi-venture operating company — it has the financial backing of a corporate parent but operates independently, with its own board and capital allocation. This allows longer development timelines typical of life sciences R&D, while still facing profit expectations from Alphabet.
General information
Firm type
Single Family Office
Year founded
2015
AUM
$10B – $20B (Altss estimate)
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, CA, United States
Principals
Andy Conrad
CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Verily?
Andy Conrad, CEO of Verily, oversees the company's strategic direction and resource allocation. Clinical research and product decisions are made by a team of scientists and engineers. The parent company Alphabet provides oversight through its board structure.
How does Verily source proprietary deal flow?
Verily relies on their internal research and development capabilities, partnerships with academic medical centers and pharmaceutical companies, and strategic relationships within Alphabet. Notable collaborations include a joint venture with Johnson & Johnson for Verb Surgical and with GlaxoSmithKline for Galvani Bioelectronics (per Reuters, 2016).
Is Verily structured as a single family office or does it operate more like a venture firm?
Verily is structured as a wholly owned subsidiary of Alphabet, functioning more like an operating company within a corporate venture context. While it makes strategic investments and partnerships, its primary model involves developing its own products such as the Study Watch and Onduo platform.
What investment stages does Verily typically target?
Verily focuses on early-stage to growth-stage opportunities in life sciences and healthcare technology. They engage in direct investments in companies aligned with their precision health thesis and also form joint ventures with large pharmaceutical and medical device companies.
Where does the underlying wealth come from?
Verily is funded by Alphabet Inc. (the parent company of Google), which generates its wealth from digital advertising, cloud services, and other technology businesses. Alphabet's market capitalization exceeds $1.5 trillion as of 2025.
Does Verily maintain philanthropic structures, and how are they separated?
Verily has a philanthropic arm focused on global health data access, separate from its commercial operations. This entity funds research and open-source data platforms, distinct from Alphabet's philanthropic arm Google.org.
What is Verily's known posture on co-investments alongside external GPs?
Verily primarily conducts investments through its own balance sheet and does not typically co-invest alongside external general partners in the traditional sense. Instead, it forms strategic partnerships and joint ventures with industry leaders such as Johnson & Johnson and GSK.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: